Skip to content
type1.science
Phase 3Active, not recruitingNCT05018585

DIAGNODE-3: Intralymphatic GAD-alum in HLA DR3-DQ2 recent-onset T1D

Phase-3 trial of Diamyd (GAD-alum) in adolescents and adults with recently diagnosed T1D who carry the HLA DR3-DQ2 haplotype, the subgroup where prior antigen-specific immunotherapy signals have been strongest.

Primary endpoints

  • Preservation of endogenous beta-cell function and glycemic outcomes

Results so far

No results posted as of the April 2026 registry update reviewed here.

The full picture

DIAGNODE-3 is the pivotal antigen-specific immunotherapy trial the current GAD record was missing: not general-population prevention, but a genetically targeted attempt to preserve insulin production after diagnosis.